BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/15/2023 1:46:53 PM | Browse: 140 | Download: 575
 |
Received |
|
2023-09-07 03:01 |
|
Peer-Review Started |
|
2023-09-07 03:01 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-09-15 22:34 |
|
Revised |
|
2023-09-23 10:19 |
|
Second Decision |
|
2023-09-27 02:53 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-09-27 10:55 |
|
Articles in Press |
|
2023-09-27 10:55 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-10-05 03:29 |
|
Typeset the Manuscript |
|
2023-11-03 08:26 |
|
Publish the Manuscript Online |
|
2023-11-15 13:46 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Rui Feng, De-Xin Cheng, Xiao-Chen Chen, Liu Yang and Hao Wu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hao Wu, MM, Attending Doctor, Department of Vascular Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou 310000, Zhejiang Province, China. wuhao89899@163.com |
| Key Words |
Microsatellite stability; Colorectal cancer; Sintilimab; Anlotinib hydrochloride; Immunity; prognosis |
| Core Tip |
In the treatment of microsatellite stable (MSS) colorectal cancer (CRC), the combination of monoclonal antibody therapy and hydrochloride anlotinib has shown encouraging results. Monoclonal antibodies specifically target and block certain proteins involved in tumor growth, while hydrochloride anlotinib acts as a multi-kinase inhibitor, inhibiting multiple signaling pathways associated with cancer progression. Preclinical and early clinical studies have shown that this combination therapy has the potential to enhance antitumor immune responses and inhibit tumor growth in MSS CRC. By targeting both the tumor microenvironment and the signaling pathways crucial for cancer cell survival, this dual approach may provide a synergistic effect, leading to improved treatment response and prolonged survival in patients with MSS-CRC In summary, the combination of monoclonal antibody therapy and hydrochloride anlotinib may offer a new treatment option for patients with MSS CRC. |
| Publish Date |
2023-11-15 13:46 |
| Citation |
Feng R, Cheng DX, Chen XC, Yang L, Wu H. Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1925-1935 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i11/1925.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i11.1925 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
